Compare FMC Corp (FMC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Pfizer Inc — how do they compare? FMC Corp trades at $8.89 (market cap $1.41B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 113.2× FMC Corp's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Pfizer Inc for 158 Days on average.
| FMC | PFE | |
|---|---|---|
Market Cap | $1.41B | $159.59B |
Volume | 4,507,459 | 30,937,010 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $29.02 |
52-Week Low | $8.44 | $23.67 |
Typical Hold Time | 68 Days | 158 Days |
Enterprise Value | $5.22B | $211.09B |
Dividend Yield | 3.52% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.92, down 1.22% on the day, with a bearish technical signal and negative profitability metrics including a net income margin of -84.83% and ROE of -91.47% for 2025. Recent news highlights regulatory progress with rimisoxafen in Brazil and a minority equity investment from Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227.20M but driven by financing activities as operating cash flow was negative.
The outlook is challenged by significant losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include sustained negative margins, industry cyclicality, and execution of deleveraging plans. The stock presents a high-risk opportunity contingent on operational turnaround and debt reduction success.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
